Stock Events

Exelixis 

€20.53
104
+€0.13+0.64% Friday 06:23

Statistics

Day High
20.53
Day Low
20.53
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
6.52B
P/E Ratio
31.82
Dividend Yield
-
Dividend
-

Earnings

30AprConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.11
0.04
0.18
0.33
Expected EPS
0.23
Actual EPS
0.17

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EX9.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap82.02B
Bristol Myers Squibb competes in the oncology space with a broad portfolio of cancer treatments, overlapping with Exelixis's focus on cancer therapeutics.
Merck &
MRK
Mkt Cap323.59B
Merck is a leading competitor in the oncology market, particularly with its blockbuster cancer drug Keytruda, which competes in indications similar to those of Exelixis's products.
Pfizer
PFE
Mkt Cap163.88B
Pfizer has a diverse oncology portfolio that includes treatments for various types of cancer, directly competing with Exelixis's cancer therapies.
Astrazeneca
AZN
Mkt Cap245.69B
AstraZeneca operates in the same therapeutic areas as Exelixis, with a strong focus on oncology and a pipeline of cancer drugs that compete with Exelixis's offerings.
Roche
RHHBY
Mkt Cap200.6B
Roche, through its Genentech division, develops and markets oncology drugs that compete with Exelixis's cancer treatments, particularly in the areas of targeted therapy and immunotherapy.
Novartis
NVS
Mkt Cap244.62B
Novartis competes with Exelixis in the oncology sector, offering a range of cancer treatments that overlap with Exelixis's therapeutic areas.
Gilead Sciences
GILD
Mkt Cap87.16B
Gilead Sciences, with its acquisition of Kite Pharma, has expanded its oncology portfolio, competing with Exelixis in the cancer treatment market.
AMGEN
AMGN
Mkt Cap177.47B
Amgen has a presence in the oncology market with treatments that compete against Exelixis's cancer therapies, including targeted therapies and biologics.
Regeneron Pharmaceuticals
REGN
Mkt Cap118.74B
Regeneron Pharmaceuticals competes in the oncology space with a focus on innovative cancer treatments, including immunotherapies that rival Exelixis's products.
Incyte
INCY
Mkt Cap14.29B
Incyte Corporation has a portfolio of oncology products that directly compete with Exelixis's cancer therapies, particularly in the areas of targeted therapy and immunotherapy.

Analyst Ratings

26.14Average Price Target
The highest estimate is €28.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
43%
Hold
57%
Sell
0%

About

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Show more...
CEO
Dr. Stelios Papadopoulos Ph.D.
Employees
1310
Country
US
ISIN
US30161Q1040
WKN
000936718

Listings